Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04440735 · ClinicalTrials.gov registry record · Phase 1
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Kahr Medical.
- Active
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 7
- Study locations
NCT04440735: Active Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Kahr Medical.
NCT04440735 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is active but no longer recruiting, run by Kahr Medical. The registered enrollment target is 125 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (81% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04440735, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is active but no longer recruiting, sponsored by Kahr Medical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 7
- Study locations
Study Summary
Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.
Primary Outcome
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Conditions Studied
Interventions
- BIOLOGICAL Atezolizumab
- BIOLOGICAL DSP107
Study Locations (7)
Pennsylvania
- SKCC-Sidney Kimmel Cancer Center Thomas Jefferson University - Philadelphia
- UPMC Hillman Cancer Center University of Pittsburgh - Pittsburgh
California
- Moores Cancer Center, UCSD - La Jolla
Colorado
- University of Colorado Hospital, Anschutz Cancer Pavilion (ACP) - Aurora
Florida
- Florida Cancer Specialists - Lake Mary
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Kansas
- KUCC / KUMCRI University of Kansas Cancer Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2020-10-07 |
| Est. Completion | 2025-09 |
| Phase | Phase 1 |
What the registry record for NCT04440735 still lists
NCT04440735 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT04440735 lists 7 locations in 6 states (Pennsylvania, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT04440735 about?
NCT04440735 is a clinical study titled "A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors". Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non sma...
What is the current status of trial NCT04440735?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2020-10-07. Estimated completion is 2025-09.
What conditions does trial NCT04440735 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor.
What interventions are being tested in trial NCT04440735?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), DSP107 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04440735?
This trial is sponsored by Kahr Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04440735 being conducted?
This trial has 7 study locations across California, Colorado, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04440735's enrollment target sits among peer trials
125 216th of 454 higher than 239 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI